Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: In vitro evaluation of sequential dosing of SN38 and/or eltanexor in CRC cell lines (HCT8, HCT116, LS1034, and HCT15). (A) Dosing strategies for in vitro viability assay. Cells were incubated with SN38 [10 nM] for the first 24 hours. Cells were then washed with PBS and incubated with eltanexor [100 nM] for an additional 48 hours. (B) Cell viability % measured by CellTiter Glo 2.0 and (C) heatmaps of the 4 CRC cell lines treated sequentially with SN38 [0 - 30 nM] followed by eltanexor [0 -100 μM]. Bliss synergy score was analyzed using SynergyFinder.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: In Vitro, Viability Assay, Incubation

Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: (A) A Western blot analysis of RAD51, p53, p-H2A.X and MSH2 in CRC cell lines HCT8, HCT116, LS1034, and HCT15 following sequential treatment of SN38 and/or eltanexor. (B) Densitometry analysis total cell protein. Cells were exposed to SN38 (10 nM) or vehicle for 6hr. (C) Cells were then washed with PBS and incubated with or without the presence of eltanexor (1 uM) for an additional 24 hr. Nuclear/Cytoplasmic. (D) Densitometry analysis of nuclear/cytoplasmic proteins.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: Western Blot, Incubation

Journal: Frontiers in Oncology

Article Title: Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

doi: 10.3389/fonc.2026.1721685

Figure Lengend Snippet: Immunocytochemistry in HCT8 and HCT 116 cell lines. Cells were first treated with SN38 (10 nM) in time series (0 hr, 2 hr, 4 hr, and 6 hr). Cells were washed with PBS and then treated with eltanexor (1 uM) for 48 hours. Cells were fixed and then stained with p53 and p21 for cell cycle arrest or stained with P-H2A.X for double stained DNA breaks. (A) Schematic illustration of dosing strategy, (B) immunostaining in HCT8 cell line and (C) immunostaining in HCT116 cell line.

Article Snippet: Human CRC cell lines HCT8 (RRID: CVCL_2478), HCT15 (RRID: CVCL_0292), HCT116 (RRID: CVCL_0291), and LS1034 (RRID: CVCL_1382) were purchased from American Type Culture Collection (ATCC) (Manassas, VA; ).

Techniques: Immunocytochemistry, Staining, Immunostaining

Journal: BMC Cancer

Article Title: Up-regulation of m 6 A writer METTL14 inhibits tumorigenesis by suppressing glycolysis in colorectal cancer

doi: 10.1186/s12885-025-13532-2

Figure Lengend Snippet: Expression of METTL14 in colorectal cancer (CRC). ( A ) METTL14 expression in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) tissues from TCGA database. ( B ) METTL14 expression in stage I - IV tumors from TCGA dataset. ( C ) Kaplan and Meier Plotter predicted the correlation between the expression of METTL14 and the prognosis of CRC. ( D ) qPCR analysis of METTL14 mRNA expression in 66 human CRC tissues and matched adjacent nontumor tissues. ( E ) qPCR analysis of METTL14 mRNA levels in CRC cells lines and human normal colonic epithelial cells. n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, the data was represented by mean ± SD, and comparisons between multiple groups were performed by ANOVA followed Tukey′s post hoc test

Article Snippet: Human CRC cell lines (HCT116, DLD-1, HCT8, SW480, and SW620) purchased from American Type Culture Collection (Manassas, Virginia, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% foetal bovine serum (FBS) and 1% Penicillin/Streptomycin at an incubator with 37°C and 5% CO 2 .

Techniques: Expressing

Journal: BMC Cancer

Article Title: Up-regulation of m 6 A writer METTL14 inhibits tumorigenesis by suppressing glycolysis in colorectal cancer

doi: 10.1186/s12885-025-13532-2

Figure Lengend Snippet: Identification of potential downstream target of METTL14 in CRC. ( A ) METTL14 related genes in CRC were obtained from LinkedOmics. ( B ) Funrich analysis of METTL14 related genes. ( C ) m 6 A levels of genes enriched in mTOR signaling pathway were detected in DLD-1 cells before and after METTL14 over-expression obtained by MeRIP-qPCR analysis. ( D ) RIP-qPCR analysis was carried out to verify the binding relationship between METTL14 protein and ATF2 RNA. ( E ) Seven potential m 6 A modification sites of ATF2 were predicted by SRAMP. ( F ) Relative luciferase activity of wild-type and mutant ATF2 in DLD-1 cells before and after METTL14 over-expression obtained by Dual-Luciferase Reporter Assay analysis. ( G ) ATF2 mRNA levels in DLD-1 cells before and after METTL14 over-expression under the interference of ACD at 0, 4, 8, and 12 h. n = 3, ** p < 0.01, *** p < 0.001, the data was represented by mean ± SD, and unpaired Student′s t-test was used for the data of two-group analysis

Article Snippet: Human CRC cell lines (HCT116, DLD-1, HCT8, SW480, and SW620) purchased from American Type Culture Collection (Manassas, Virginia, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% foetal bovine serum (FBS) and 1% Penicillin/Streptomycin at an incubator with 37°C and 5% CO 2 .

Techniques: Over Expression, Binding Assay, Modification, Luciferase, Activity Assay, Mutagenesis, Reporter Assay